Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of acylaminobenzoic acids and derivatives. It is structurally characterized as a benzoic acid in which the hydrogens at positions 3 and 4 have been replaced by pentan‑3‑ylamino and 2,2‑bis(hydroxymethyl)-5‑oxopyrrolidin‑1‑yl groups. The molecule contains both primary alcohol and secondary amine functionalities. It has not been approved for any therapeutic use or clinical indication and is classified as an experimental compound with no known mechanism of action or established pharmacological activity in humans[1][2][9]. There are no reported clinical trials or marketed products containing this substance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-[4-Carboxy-2-(3-pentylamino)phenyl]-5,5'-di(hydroxymethyl)pyrrolidin-2-one.